MD Anderson researchers, led by Renata Ferrarotto, conducted a phase II trial evaluating the combination of the VEGFR inhibitor axitinib plus the PD-L1 inhibitor avelumab in 28 patients with progressive recurrent or metastatic adenoid cystic carcinoma, a rare salivary gland cancer for which there are limited treatment options.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
